re: AUPH - Aurinia Pharmaceuticals

quote:

---

As we reflect back on the past year, one thing is clear – there has been significant progress, not only in awareness, but also in lupus research and advocacy efforts to secure additional research funding for lupus. We are encouraged by the advances of 2017 and look forward to reporting on more successes during 2018 and beyond, with great hope of a better quality of life for all people affected by lupus!

---

quote:

---

Great Progress in the Development of an Arsenal of New Treatments - Results of several clinical trials provided good reasons for people with lupus to remain hopeful that more effective and tolerable treatments are right around the corner.

Voclosporin - A phase IIb clinical study of voclosporin for treating lupus nephritis (lupus affecting the kidneys) showed nearly half of the participants who received a low dose of voclosporin, along with standard of care, achieved complete remission after 48 weeks of treatment. The research is continuing and a phase III trial, Aurora, began in late May of 2017.

---